Explore more price target data and ratings for MannKind Corporation on the Forecasts tab, and track all previous and future analyst recommendations for MannKind Corporation in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This info…
Q2 revenue grew 43% year-over-year, driven by Afrezza pediatric launch and FUROSCIX growth. ReadyFlow approval and strong nintedanib DPI data position the company for continued momentum, with guidance reaffirmed and margin expansion expected in 2027.Based on MannKind Corporation [MNKD] Q2 2026 Audi…
Q2 2026 delivered strong revenue growth, led by Afrezza pediatric launch and Furoscix, with marketed products surpassing royalties as the main revenue source. Key product approvals and positive clinical data support continued momentum into the second half of 2026.Original document: MannKind Corpora…
Q2 revenue grew 43% year-over-year, driven by strong Afrezza and FUROSCIX sales, with pediatric Afrezza launch showing robust early adoption and FUROSCIX ReadyFlow set for imminent launch. Investments in launches and R&D led to a net loss, but cash position remains strong.Based on MannKind Corporat…
MannKind Corporation (NASDAQ:MNKD) won FDA clearance for Furoscix ReadyFlow autoinjector for at‑home furosemide with urine output matching IV, advanced a nintedanib DPI from INFLO‑1 into global Phase 2 after strong Phase 1b safety, set Q2 results and call for Aug 5, and drew a Wells Fargo price tar…
Phase I-B results for nintedanib DPI in IPF patients showed strong safety and tolerability, with no serious adverse events or GI issues and only mild, transient cough in a minority of patients. The Technosphere DPI platform achieved efficient lung delivery, supporting advancement to a global phase…
Phase I-B results for nintedanib DPI in IPF patients showed a clean safety profile, with no serious adverse events, no GI issues, and transient mild-to-moderate cough in a minority of patients. The drug achieved efficient lung delivery and is advancing to a global phase II trial with broad patient…
Phase 1b results for Nintedanib DPI in IPF patients showed strong safety and tolerability, with no serious adverse events or discontinuations. The DPI formulation achieved efficient lung delivery and high peak concentrations, supporting its potential as a backbone therapy for IPF as Phase 2 enrollm…
Phase 1b results show nintedanib DPI is safe and well tolerated in IPF patients, with no serious adverse events or discontinuations and only mild, transient cough. The ongoing Phase 2 trial will further assess safety, tolerability, and efficacy.Original document: MannKind Corporation [MNKD] Press r…
Shares of MannKind Corporation (MNKD) jumped 8% on Friday after the company said that the U.S. Food and Drug Administration has approved Furoscix ReadyFlow, a simple autoinjector designed to treat fluid buildup, known as edema, in adults with heart failure or chronic kidney disease.The device is th…
FDA approved FUROSCIX ReadyFlow, a rapid subcutaneous auto-injector for IV-equivalent furosemide, enabling at-home treatment for fluid overload. Clinical data confirmed bioequivalence and safety, with broad U.S. launch planned in Q3 2026 and alignment with upcoming CMS incentives.Based on MannKind…
FDA approved Furoscix ReadyFlow, the first IV-equivalent furosemide auto-injector, enabling rapid, at-home treatment for fluid overload. Clinical data confirmed bioequivalence and safety, with launch set for Q3 2026 and broad adoption expected across care settings.Based on MannKind Corporation [MNK…
FDA approved Furoscix ReadyFlow, the first autoinjector delivering IV-equivalent furosemide for adults with heart failure or chronic kidney disease. The device enables rapid, at-home treatment of edema, with commercial launch expected by August 2026.Original document: MannKind Corporation [MNKD] Pr…
DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 24, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation NASDAQ:MNKD, a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced tha…
Furoscix ReadyFlow [prototype]WESTLAKE VILLAGE, Calif., and BOSTON, July 24, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation NASDAQ:MNKD, a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseas…
